One Health: A ‘digital twin’ model for predicting cancer outcomes

Promotional graphic highlighting the theme of One Health with images of scientific research, agriculture, and veterinary care.

Purdue Veterinary Medicine scholars involved in new bladder cancer research initiative

The striking similarities between invasive bladder cancer in dogs and humans have fueled research advances for more than three decades. Most of that work has looked at separate aspects of the disease — risk factors, early detection, symptoms, treatment and gene expression. But a new project at Purdue University that combines many types of available data in a “digital twin” model of bladder cancer may prove powerful enough to predict patient outcomes, starting with the probability of metastasis.

Nadia Atallah Lanman, PhD
Nadia Atallah Lanman, PhD

“We want to be able to look at a tissue sample from a patient and say, ‘This person’s tumor has these features that we’ve seen can predict metastasis with a reasonable degree of certainty, so we should treat that patient as aggressively as possible,’” said Nadia Lanman, PhD, a research associate professor of comparative pathobiology in the College of Veterinary Medicine and manager of the Collaborative Core for Cancer Bioinformatics. “We’re leveraging data from dogs to learn more about cancer in humans, which hopefully helps both our canine friends and human patients.”

The tools created at Purdue could be adapted across the animal kingdom, with insights in one species feeding discovery in the others and accelerating knowledge and therapeutics. The project draws on the expertise of six Purdue faculty members, including Deborah Knapp, DVM, MS, DACVIM-Oncology, a canine cancer scientist and the Dolores L. McCall Professor of Comparative Oncology in the College of Veterinary Medicine, who leads a long-running study of dogs with bladder cancer including Scottish terriers, a breed that develops bladder cancer at a rate 20 times higher than other dog breeds.

“Where before we could look at maybe three types of data at a time, my expectation is that we’re going to be able to feed many, many data types into this model and use it to simulate scenarios across all those data types,” Dr. Knapp said. “It’s likely that we’re going to be able to answer clinical questions that we can’t yet answer.”

Lanman said the project will likely build two comprehensive models — one focused on canine data and one on human data — which will be used to help inform each other. As its name suggests, a digital twin model uses data and computing techniques to create a virtual representation of its real-world counterpart for the purposes of experimentation and simulation. The team is beginning its work by using the canine model to ask questions about canine metastasis — spread of cancer cells from the original tumor — of bladder cancer.

“Metastasis is hard to study and there’s not a lot known about how it occurs and the similarities between the primary tumor and the metastasis, so there’s a lot of basic biology to figure out,” Lanman said. “The canine data gives us the opportunity to look at metastasis in a way that we can’t in humans because we don’t have access to metastatic tumor samples, which are not generally surgically removed from human patients. The canine data will help us know what features to look at in the human data.”

Deborah W. Knapp, DVM, MS, DACVIM-Oncology
Deborah W. Knapp, DVM, MS, DACVIM-Oncology

The digital twin model combines machine learning techniques with Dr. Knapp’s veterinary data, human health records, an image classification system the project is developing and new molecular data being commissioned for the project.

“Leveraging Cross-species Digital Twins for Modeling Cancer Progression and Outcome” is one of four research projects awarded seed grant funding through a university-wide life and health sciences summit held in November 2023. The research, which studies and would benefit both animals and humans, is part of Purdue’s One Health initiative, a presidential initiative that involves research at the union of humans, animals and plants.

“What is happening to both dogs and humans that leads to bladder cancer? Is it aging, genetics, something in the environment? Our shared experience with our pets makes this a compelling space to explore,” said Kaethe Beck, Purdue assistant vice president for strategic impact in life and health sciences. “And while this project focuses on bladder cancer in dogs and humans, the algorithms that the researchers will develop aren’t unique to dogs or humans; they will have application across species and diseases.”

In diseases where similarities exist between dogs and humans, modeling across species can be helpful for several reasons, Lanman said. Dogs receive veterinary care, and the data collected in their treatment is less restricted than human health records. And after the dog has died, owners will often allow researchers to collect tissue samples from the primary tumor as well as metastatic tumors, an option that is rarely possible with humans.

Dr. Knapp said many known similarities between invasive bladder cancer in Scottish terriers and humans make the cross-species comparison ideal. In both species, some of the same genes are involved in the disease — and they share mutations that lead to cancer. In both dogs and humans, the cancers appear similar under a microscope and metastasize to similar locations in the body at a similar rate. At the molecular level, the cancer can be divided into two major molecular subtypes that affect how the cancer will behave.

Dr. Knapp’s research on Scottish terriers has already paid dividends in understanding human bladder cancer. Her team’s most recent work found an environmental factor — exposure to cigarette smoke — that increases cancer risk in dogs, and has led to new techniques for early detection and treatment of cancer. The new model may yield additional insights in areas like environmental or genetic factors, early signs and symptoms, immune response, drug response and metastasis.

To help inform the model, the team is using AI tools to analyze images of tumor cells. In the first step, researchers manually label about 50 cells in a tumor image that display recognizable characteristics of cancer, such as abnormal shape or an overly large nucleus. The image, with labeled cells, is fed into an AI program that “learns” to make an accurate prediction about the characteristics of unlabeled cells. Then the computer labels the remaining cells in the image, processing an entire image of thousands of cells quickly and improving the accuracy of the algorithm with each attempt.

The labeled images, separated into different categories — such as those that responded well to treatment, those that metastasized or those from patients with a similar health history — will be introduced to additional AI tools that extract the features associated with those cancer types. When incorporated into the larger digital twins model, with its wide breadth of data types, this information will aid in predicting the course of newly diagnosed cancers.

The model’s predictions can also be used to inform additional preclinical models, using that information to develop therapies to address those aspects of the disease.

“Why does bladder cancer spread throughout the body in one person, or one dog, and why does it stay confined to the urinary system for months to years in another individual? Everything we’ve learned so far can give you information about groups — like what subtype the cancer is — but we can’t say ‘this individual will have metastasis,’” Dr. Knapp said. “The digital twin model may lead to our ability to predict what will happen in the individual. And that will be really powerful.”

In addition to Knapp and Lanman, both of whom are members of the Purdue Institute for Cancer Research, the research team includes Vaneet Aggarwal, a professor in the Edwardson School of Industrial Engineering in the College of Engineering; Ananth Grama, Samuel D. Conte Distinguished Professor of Computer Science in the College of Science; Seung-Oe Lim, an associate professor in the Borch Department of Medicinal Chemistry and Molecular Pharmacology in the College of Pharmacy; and Mario Sola, clinical assistant professor in the College of Veterinary Medicine’s Department of Comparative Pathobiology.

Writer(s): Mary Martialay | pvmnews@purdue.edu

Recent Stories

“Paws Up” – brought to you by the PVM Wellness Committee

Behind the scenes, Alicia Williams has been making PVM a kinder, stronger place.

Purdue Veterinary Medicine Computational Biologist Uses Big Data, AI and Math to Find Patterns in Cancer

With recent advances, cancer research now generates vast amounts of information. The data could help researchers detect patterns in cancer cells and stop their growth, but the sheer volume is just too much for the human mind to digest. Enter Nadia Lanman, research associate professor in the Department of Comparative Pathobiology, whose expertise in computational biology helps researchers at Purdue University distill solutions from the sea of numbers.

Purdue to Host Fourth Annual Antimicrobial Conference in February

With leadership by the Purdue University College of Veterinary Medicine, the Fourth Annual Conference on Antimicrobial Resistance (AMR) will be held at Purdue University West Lafayette February 25–26, 2026. With multidrug-resistant infections on the rise globally, this event brings together experts and practitioners across the spectrum of human, animal, and environmental health to address one of today’s most urgent public health challenges.

PVM Well-represented by Humans and Animals During Annual Homecoming Celebrations

Every fall, Boilermakers from near and far return to the campus in West Lafayette for the annual ritual known as Homecoming. And Purdue’s Homecoming events also attract plenty of non-alumni who are Purdue fans, patrons, prospective students, or clients of the Purdue University Veterinary Hospital. During this year’s Homecoming weekend October 24-25, Purdue Veterinary Medicine engaged with attendees in multiple ways, with the help of some furry companions.

Purdue University and Akston Biosciences Bring “First Dose of Hope” in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer

The Purdue University College of Veterinary Medicine, in partnership with Akston Biosciences Corporation, has initiated the enrollment of dogs with urinary bladder cancer in a clinical trial of a pioneering immunotherapy. The strategic partnership between Purdue and Akston was announced in August after the underlying technology was developed at the College of Veterinary Medicine and the Purdue Institute for Cancer Research (PICR).

“Paws Up” – brought to you by the PVM Wellness Committee

Today we share appreciation for Beth Laffoon, MS, RVT, and Holly McCalip, BS, RVT, who are both instructional technologists in the Veterinary Nursing Program.

MMAS Symposium Brings Participants Face to Face with Specialists and Species from Parrots to Pocket Pets

Thanks to Purdue Veterinary Medicine’s Exotic Animal Club and dedicated faculty, staff and students, nearly 100 in-person and on-line participants got a chance recently to gain valuable knowledge and insight about the Medicine of Mammalian and Avian Species. The two-day educational event known as the MMAS Symposium is a biennial conference, and the 2024 edition held in Lynn Hall November 9 and 10 featured an impressive program that included 22 lectures and several hands-on labs, organized into two tracks focusing on avian and mammalian species.

Veterinary Boilermakers Take Part in Purdue One Health Alumni Reunion

Purdue University College of Veterinary Medicine faculty, staff and students turned out for Purdue University’s first One Health Alumni Reunion, which was held on the West Lafayette campus November 14-16. They joined more than 150 Boilermakers from a variety of medical professions who came together to network and participate in timely discussions with Purdue President Mung Chiang, First Lady Kei Hui and fellow alumni.